Post-translational modifications of histones by protein methyltransferases (PMTs) and
histone demethylases (KDMs) play an important role in the regulation of gene expression …

Histone lysine‐specific demethylase 1 (LSD1) is the first discovered and reported histone
demethylase by Dr. Shi Yang's group in 2004. It is classified as a member of amine oxidase …

There is increasing interest in targeting histone N-methyl-lysine demethylases (KDMs) with
small molecules both for the generation of probes for target exploration and for therapeutic …

Histone lysine-specific demethylase 1 (LSD1/KDM1A) has become an important and
promising anticancer target since it was first identified in 2004 and specially demethylates …

LSD1 was the first histone demethylase identified by Professor Shi Yang and his team
members in 2004. LSD1 employs FAD as its cofactor, which catalyzes the demethylation of …

Dysregulation of lysine (K)-specific demethylase 1A (LSD1), also known as KDM1A, has
been implicated in the development of various cancers, including leukemia. Here, we …

Monoamine oxidases (MAOs) catalyse the oxidation of neurotransmitter amines and a wide
variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs …

LSD1 was significantly over-expressed in several cancer types, and its aberrant
overexpression was revealed to play a crucial role in the initiation and progression of …

Due to the increasing costs and time consuming for new drug discovery, a large number of
pharmaceutical firms have chosen to modify the existing drug molecules for repositioning …

Small molecules targeting the flavin adenine dinucleotide (FAD)-dependent histone lysine
demethylase LSD family have displayed therapeutic promise against various diseases. Nine …